NASDAQ:GTHX - G1 Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $45.67
  • Forecasted Upside: 299.88 %
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$11.42
▲ +0.55 (5.06%)

This chart shows the closing price for GTHX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New G1 Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GTHX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GTHX

Analyst Price Target is $45.67
▲ +299.88% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for G1 Therapeutics in the last 3 months. The average price target is $45.67, with a high forecast of $71.00 and a low forecast of $19.00. The average price target represents a 299.88% upside from the last price of $11.42.

This chart shows the closing price for GTHX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in G1 Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
6/15/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
9/13/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/12/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
3/12/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/10/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
11/7/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/7/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/4/2021JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$20.00 ➝ $19.00Medium
11/4/2021HC WainwrightLower Price TargetBuy$78.00 ➝ $71.00Medium
11/4/2021Raymond JamesLower Price TargetOutperform$41.00 ➝ $24.00Medium
11/3/2021Roth CapitalLower Price TargetBuy$56.00 ➝ $54.00High
10/6/2021JPMorgan Chase & Co.Reiterated RatingHold$20.00Medium
9/30/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$24.00 ➝ $20.00High
9/1/2021Roth CapitalLower Price TargetBuy$57.00 ➝ $56.00Low
8/5/2021WedbushLower Price TargetIn-Line ➝ Outperform$59.00 ➝ $38.00Medium
4/9/2021Needham & Company LLCReiterated RatingBuy$68.00High
2/25/2021Needham & Company LLCLower Price TargetBuy$74.00 ➝ $68.00High
11/17/2020Raymond JamesDowngradeStrong-Buy ➝ Outperform$66.00 ➝ $21.00Medium
10/5/2020HC WainwrightReiterated RatingBuy$82.00Medium
8/20/2020WedbushReiterated RatingBuy$46.00Medium
8/18/2020HC WainwrightReiterated RatingBuy$82.00High
8/9/2020CowenReiterated RatingBuyHigh
8/6/2020WedbushLower Price TargetOutperform$50.00 ➝ $46.00High
8/3/2020Needham & Company LLCReiterated RatingBuy$74.00Medium
8/3/2020HC WainwrightReiterated RatingBuyMedium
7/1/2020Needham & Company LLCReiterated RatingBuy$74.00Medium
7/1/2020WedbushLower Price TargetOutperform$55.00 ➝ $50.00High
6/26/2020Roth CapitalInitiated CoverageBuy$55.00Medium
6/22/2020Needham & Company LLCReiterated RatingBuy$74.00Low
5/12/2020JPMorgan Chase & Co.Lower Price TargetOverweight$33.00 ➝ $23.00High
2/27/2020WedbushLower Price TargetOutperform$67.00 ➝ $55.00High
1/21/2020HC WainwrightReiterated RatingBuy$72.00 ➝ $82.00High
1/7/2020BTIG ResearchBoost Price TargetPositive ➝ Buy$51.00 ➝ $80.00Low
12/12/2019CowenReiterated RatingBuyHigh
12/12/2019Needham & Company LLCReiterated RatingBuy$74.00High
12/12/2019HC WainwrightReiterated RatingBuy$72.00High
11/6/2019CowenReiterated RatingBuyHigh
11/6/2019HC WainwrightReiterated RatingBuy$72.00High
9/30/2019Needham & Company LLCSet Price TargetBuy$74.00Low
9/30/2019CowenReiterated RatingBuyLow
9/30/2019HC WainwrightSet Price TargetBuy$72.00Low
9/27/2019B. RileySet Price TargetBuy$55.00Low
9/24/2019Needham & Company LLCSet Price TargetBuy$74.00Low
9/13/2019CowenReiterated RatingBuyHigh
9/11/2019HC WainwrightReiterated RatingBuy$72.00High
8/8/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$38.00 ➝ $45.00High
6/18/2019CowenReiterated RatingBuyHigh
6/2/2019CowenReiterated RatingBuyHigh
5/10/2019CowenReiterated RatingBuyHigh
3/6/2019CowenReiterated RatingBuyHigh
3/1/2019WedbushReiterated RatingOutperform$67.00High
2/7/2019B. RileyInitiated CoverageBuy ➝ Buy$55.00 ➝ $55.00Medium
1/23/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$59.00 ➝ $41.00High
12/21/2018CowenReiterated RatingBuyMedium
12/20/2018WedbushReiterated RatingOutperform$67.00High
12/19/2018Raymond JamesInitiated CoverageStrong-Buy ➝ Strong-BuyHigh
11/11/2018CowenReiterated RatingBuyHigh
11/8/2018Needham & Company LLCLower Price TargetBuy$76.00 ➝ $74.00High
9/18/2018Needham & Company LLCBoost Price TargetBuy$76.00High
9/17/2018HC WainwrightReiterated RatingBuy$79.00Low
9/10/2018BTIG ResearchInitiated CoverageBuy ➝ Buy$80.00High
8/10/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$58.00 ➝ $63.00Low
8/9/2018CowenReiterated RatingBuyHigh
5/29/2018HC WainwrightInitiated CoverageBuy$61.00Medium
5/18/2018Needham & Company LLCBoost Price TargetBuy$42.00 ➝ $60.00High
3/13/2018Needham & Company LLCBoost Price TargetBuy$42.00High
3/7/2018BTIG ResearchReiterated RatingBuy$48.00High
3/6/2018JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Overweight$33.00 ➝ $39.00High
3/5/2018CowenReiterated RatingBuyLow
2/22/2018BTIG ResearchReiterated RatingBuy$38.00High
2/5/2018JPMorgan Chase & Co.Boost Price Target$30.00High
12/19/2017BTIG ResearchInitiated CoverageBuy$38.00Low
11/8/2017CowenReiterated RatingBuyN/A
8/9/2017CowenReiterated RatingBuyLow
6/12/2017WedbushInitiated CoverageOutperform$31.00High
6/12/2017Needham & Company LLCInitiated CoverageBuy ➝ Buy$34.00High
6/12/2017CowenInitiated CoverageOutperform$31.00High
6/12/2017JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$23.00High
(Data available from 12/7/2016 forward)

News Sentiment Rating

0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/11/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/10/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/10/2021
  • 7 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
8/9/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/8/2021
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/8/2021
  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/7/2021
  • 3 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
12/7/2021

Current Sentiment

  • 3 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
G1 Therapeutics logo
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
Read More

Today's Range

Now: $11.42
Low: $11.14
High: $11.78

50 Day Range

MA: $13.53
Low: $10.65
High: $16.17

52 Week Range

Now: $11.42
Low: $9.95
High: $37.07

Volume

792,309 shs

Average Volume

1,158,170 shs

Market Capitalization

$485.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.17

Frequently Asked Questions

What sell-side analysts currently cover shares of G1 Therapeutics?

The following Wall Street research analysts have issued reports on G1 Therapeutics in the last twelve months: HC Wainwright, JPMorgan Chase & Co., Needham & Company LLC, Raymond James, Roth Capital, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for GTHX.

What is the current price target for G1 Therapeutics?

6 Wall Street analysts have set twelve-month price targets for G1 Therapeutics in the last year. Their average twelve-month price target is $45.67, suggesting a possible upside of 320.1%. HC Wainwright has the highest price target set, predicting GTHX will reach $71.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $19.00 for G1 Therapeutics in the next year.
View the latest price targets for GTHX.

What is the current consensus analyst rating for G1 Therapeutics?

G1 Therapeutics currently has 1 sell rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GTHX will outperform the market and that investors should add to their positions of G1 Therapeutics.
View the latest ratings for GTHX.

How do I contact G1 Therapeutics' investor relations team?

G1 Therapeutics' physical mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The company's listed phone number is (919) 213-9835 and its investor relations email address is [email protected] The official website for G1 Therapeutics is www.g1therapeutics.com.